NASDAQ : TRAW
Traws Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.301 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.60M |
| Enterprise Value | -413,201 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 15.37M |
| Shares Outstanding | 15.37M |
| Shares Change (YoY) | +138.41% |
| Shares Change (QoQ) | +49.09% |
| Owned by Insiders (%) | 6.51% |
| Owned by Institutions (%) | 27.23% |
| Float | 12.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.93 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -433.36% |
| Return on Assets (ROA) | -99.40% |
| Return on Invested Capital (ROIC) | -270.57% |
| Return on Capital Employed (ROCE) | -1,241.73% |
| Weighted Average Cost of Capital (WACC) | 12.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.35M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -89.35% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 25.01 |
| Average Volume (20 Days) | 185,448 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 685,721 |
| Short Previous Month | 690,685 |
| Short % of Shares Out | 4.46% |
| Short % of Float | 5.28% |
| Short Ratio (days to cover) | 0.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.54M |
| Pretax Income | -21.57M |
| Net Income | -16.44M |
| EBITDA | -21.40M |
| EBIT | -21.54M |
| Earnings Per Share (EPS) | -$1.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.02M |
| Total Debt | n/a |
| Net Cash | 5.02M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 1.69M |
| Book Value Per Share | 0.11 |
| Working Capital | -712,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.85M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 147,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.85M |
| FCF Per Share | -$1.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -138.41% |
| Shareholder Yield | -138.41% |
| Earnings Yield | -491.91% |
| FCF Yield | -370.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.00 |
| Price Target Difference | 233.89% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -84.72 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |